Clinical trials: Cholangiocarcinoma
Metastases, Neoplasm, Colorectal Neoplasms
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to "stick", to magnetic beads (MTCs). MTCs are tiny, microscopic particles of iron and carbon.
- Conditions
- Metastases, Neoplasm, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms
- Trial name
- NCT00041808
- Testing
- MTC-DOX for Injection, Chemotherapy
- Where
- 4 sites in United States, Germany
- Volunteers
- 20 people
- Sponsor
- FeRx
Colorectal Cancer Metastatic, Intrahepatic Cholangiocarcinoma
Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy
The goal of this clinical trial is to help learn about the safety and feasibility of hepatic artery infusion chemotherapy for those who have colorectal liver metastases, both resectable and unresectable, or unresectable…
- Trial name
- NCT07201519
- Testing
- Hepatic Artery Infusion Pump (HAIP), Standard Treatment, Community Treatment
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Michael J Cavnar, MD
Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder
Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
This phase II trial is studying how well bortezomib works as first-line systemic therapy in treating patients with unresectable locally advanced or metastatic adenocarcinoma (cancer) of the bile duct or gallbladder.
- Conditions
- Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Advanced Adult Primary Liver Cancer, Gastrointestinal Cancer
- Trial name
- NCT00085410
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
This randomized phase II trial studies how well trametinib or combination chemotherapy works in treating patients with refractory or advanced biliary or gallbladder cancer or that cannot be removed by surgery.
- Conditions
- Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma, BCLC Stage D Adult Hepatocellular Carcinoma
- Trial name
- S1310 (NCT02042443)
- Testing
- Capecitabine, Fluorouracil, Laboratory Biomarker Analysis
- Where
- 295 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Hilar Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma
RALPPS in Patients With Hilar and Intrahepatic Cholangiocarcinoma
Unsatisfactory immediate outcomes of Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) in surgery of cholangiocarcinoma suggested that patients with biliary cancer should not be treated by ALPPS.
- Trial name
- NCT03320980
- Testing
- RALPPS, portal vein embolization + major liver resection
- Volunteers
- 30 people
- Sponsor
- Moscow Clinical Scientific Center
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Ovarian Neoplasms, Breast Neoplasms
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP).
- Conditions
- Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms
- Trial name
- FiREBOLT (NCT07213791)
- Testing
- LY4337713
- Where
- 30 sites in United States, China and 3 more
- Volunteers
- 340 people
- Sponsor
- Eli Lilly and Company
Ampullary Carcinoma, Duodenal Adenocarcinoma
Modified Single-Incision Plus One-Port Versus Conventional Five-Port Laparoscopic Pancreaticoduodenectomy for Nonpancreatic Periampullary Adenocarcinomas
This multicenter, randomized, controlled, non-inferiority trial will compare modified single-incision plus one-port laparoscopic pancreaticoduodenectomy (mSILPD+1) with conventional five-port laparoscopic pancreaticoduodenectomy…
- Conditions
- Ampullary Carcinoma, Duodenal Adenocarcinoma, Distal Cholangiocarcinoma
- Trial name
- NCT07744087
- Testing
- Modified Single Incision plus one-port Laparoscopic Pancreaticoduodenectomy, Conventional Laparoscopic Pancreaticoduodenectomy
- Where
- 4 sites in China
- Volunteers
- 232 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Cholangiocarcinoma, Gall Bladder Carcinoma
Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer
This is a multicenter, prospective, randomized, controlled phase III trial designed to assess the clinical performance of gemcitabine with cisplatin and observation vs.
- Trial name
- ACTICCA-1 (NCT02170090)
- Testing
- Gemcitabine, Cisplatin, Capecitabine
- Where
- 67 sites in Australia, Austria and 6 more
- Volunteers
- 789 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Pancreatic Cancer, Breast Cancer
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05215574
- Testing
- NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
- Where
- 9 sites in United States
- Volunteers
- 130 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Colorectal Adenocarcinoma, Gastric Adenocarcinoma
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
This phase I/II trial studies the best dose and how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) and nanoliposomal irinotecan work in treating patients with gastrointestinal cancers that have…
- Conditions
- Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma
- Trial name
- NCT03368963
- Testing
- Nanoliposomal Irinotecan, Trifluridine and Tipiracil Hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- Emory University
Liver Transection During Laparoscopic Liver Resection
Comparison of Hydro-dissection Versus Ultrasonic Aspirator in Division of Liver Parenchyma in Laparoscopic Resection
Background: until now, there is no agreement about the safest and feasible method for liver parenchyma transection during laparoscopic liver resection.
- Trial name
- LLS (NCT03208192)
- Testing
- liver transection during laparoscopic liver resection
- Where
- Russia
- Volunteers
- 68 people
- Sponsor
- Moscow Clinical Scientific Center
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer
RATIONALE: Drugs used in chemotherapy such as gemcitabine work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Trial name
- NCT00059865
- Testing
- gemcitabine hydrochloride, pemetrexed disodium
- Where
- 41 sites in United States
- Volunteers
- 68 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cholangiocarcinoma
RFA Combined With Chemotherapy for Unresectable Cholangiocarcinoma
Extrahepatic cholangiocarcinoma is a malignant tumor that is highly malignant and difficult to diagnose and treat early. Endobiliary radiofrequency ablation (RFA) has been reported to be a beneficial treatment option for…
- Trial name
- NCT05028439
- Testing
- radiofrequency ablation, Chemotherapy drug
- Where
- China
- Volunteers
- 70 people
- Sponsor
- First People's Hospital of Hangzhou
Pancreatic Cancer, Bile Duct Cancer
Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy
The purpose of this study is to determine whether preoperative immunonutrition is effective on infectious complication and Th1/Th2 differentiation in patients with pancreaticoduodenectomy.
- Trial name
- EPIPD (NCT01256034)
- Testing
- Oral IMPACT
- Where
- Japan
- Volunteers
- 50 people
- Sponsor
- Chiba University
Intrahepatic Cholangiocarcinoma
Lenvatinib Plus PD-1 Antibody for Unresectable ICC
The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with PD-1 antibody for patients with unresectable intrahepatic cholangiocarcinoma.
- Trial name
- NCT03779100
- Testing
- Lenvatinib, PD-1 antibody
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Shi Ming
Cancer
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101972
- Testing
- monoclonal antibody RAV12
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- MacroGenics
Cholangiocarcinoma, Intrahepatic
Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma
Oncolytic viruses can selectively replicate in and destroy tumor cells. Recent studies indicate that recombinant human adenovirus type 5 (H101), which is the first approved oncolytic virus drug in the world, shows anti-tumor…
- Trial name
- NCT05124002
- Testing
- Recombinant Human Adenovirus Type 5, HAIC of FOLFOX
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma
A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-3248, an oral small molecule FGFR inhibitor, in adults with advanced tumors harboring FGFR2 and/or FGFR3…
- Conditions
- Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma
- Trial name
- NCT05242822
- Testing
- KIN-3248
- Where
- 21 sites in United States, China and 4 more
- Volunteers
- 54 people
- Sponsor
- Kinnate Biopharma
Adult Combined Hepatocellular-Cholangiocarcinoma
Liver Transplantation in Patients With Incidental Hepatocellular-cholangiocarcinoma and Intrahepatic Cholangiocarcinoma: A Single-center Experience
Liver transplantation has become an important treatment in hepatocellular cancer (HCC). While the generally determined malign indication in the world is HCC, some centers perform liver transplantation in both cholangiocarcinoma…
- Trial name
- NCT04848805
- Testing
- liver transplantation
- Where
- Turkey (Türkiye)
- Volunteers
- 279 people
- Sponsor
- Istanbul Demiroglu Bilim University